McDermott Will & Emery

EQS-News: INDUS successfully completes share buyback program

Retrieved on: 
Wednesday, April 10, 2024
Commerzbank, McDermott Will & Emery, Share repurchase, Acquisition, Treasury, Herman Kelly and Life, Security (finance)

Bergisch Gladbach, 13 March 2024 – SDAX-listed INDUS Holding AG has successfully completed the share buyback program announced on 21 February 2024.

Key Points: 
  • Bergisch Gladbach, 13 March 2024 – SDAX-listed INDUS Holding AG has successfully completed the share buyback program announced on 21 February 2024.
  • INDUS now holds 4.09% of its share capital as treasury shares.
  • “With our buyback offer we are demonstrating that we consider the purchase of our shares to be a good investment,” says Dr. Johannes Schmidt, Chairman of the Board of Management of INDUS Holding AG.
  • We now have the additional flexibility to use our own shares as an acquisition currency when purchasing new companies.”
    The share buyback program was accompanied by Commerzbank AG, Frankfurt, and McDermott Will & Emery Rechtsanwälte Steuerberater LLP.

Bracewell Expands Energy Practice With Addition of Parker Lee in New York

Retrieved on: 
Friday, March 22, 2024
McDermott Will & Emery, Dedman School of Law, Natural gas, History, Science, Carbon, Bracewell LLP, University, Helium, Hydrogen, Ammonia, SMU, Cryptocurrency

New York, New York--(Newsfile Corp. - March 22, 2024) - Bracewell LLP announced today that Parker A. Lee, an accomplished energy transactional lawyer, has joined the firm as a partner in the New York office.

Key Points: 
  • New York, New York--(Newsfile Corp. - March 22, 2024) - Bracewell LLP announced today that Parker A. Lee, an accomplished energy transactional lawyer, has joined the firm as a partner in the New York office.
  • "He is a wonderful addition to our market-leading energy practice, and I'm thrilled to welcome him to the firm."
  • Lee advises strategic companies and private equity and infrastructure funds on M&A, project development and joint venture transactions in the energy and infrastructure industries.
  • He joins Bracewell from McDermott Will & Emery LLP, where he was an energy and projects partner in the New York office.

AdTheorent Holding Company, Inc. Enters into Agreement to be Acquired by Cadent, LLC for Approximately $324 Million Representing $3.21 Per Share

Retrieved on: 
Monday, April 1, 2024
McDermott Will & Emery, Partnership, LLP, Acquisition, Disclosure, Royal Bank, Investment, Royal Bank of Canada, Machine learning, Canaccord Genuity

Upon closing of the transaction, AdTheorent will become a privately held company.

Key Points: 
  • Upon closing of the transaction, AdTheorent will become a privately held company.
  • Under the terms of the definitive merger agreement, which has been unanimously approved by AdTheorent’s Board of Directors (the “Board”), the Company’s common stockholders will receive cash consideration of $3.21 per share.
  • The definitive merger agreement also includes a 33-day “go shop” period that will allow the Company to affirmatively solicit alternative proposals from interested parties.
  • Moelis & Company LLC is acting as lead financial advisor, and Baker Botts LLP is providing legal counsel to Cadent.

BiomX Announces Closing of the Acquisition of Adaptive Phage Therapeutics and Concurrent $50 Million Financing

Retrieved on: 
Monday, March 18, 2024
DFO, McDermott Will & Emery, NESS, Cystic Fibrosis Foundation, APT, Phage therapy, Patient, Cystic fibrosis, LLP, Acquisition, Cooley LLP, Infection, OrbiMed, RBC Capital Markets, Pharmaceutical industry

CAMBRIDGE, Mass. and NESS ZIONA, Israel, March 18, 2024 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (together with its subsidiaries and/or associates, “BiomX”), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced the closing of its previously announced (March 6, 2024) acquisition (the “Acquisition”) of Adaptive Phage Therapeutics, Inc. (“APT”), a U.S.-based privately-held, clinical-stage biotechnology company pioneering the development of phage-based therapies to combat bacterial infections, and its previously announced $50 million private placement to certain institutional accredited investors, which was led by affiliates of Deerfield Management Company and the AMR Action Fund, and additional investors including the Cystic Fibrosis Foundation, OrbiMed and Nantahala Capital.

Key Points: 
  • “We are very pleased to announce the closing of the APT acquisition, which creates a leading phage company and an advanced pipeline that includes two Phase 2 assets each aimed at treating serious infections with unmet medical need,” said Jonathan Solomon, Chief Executive Officer of BiomX.
  • “We also appreciate the continued support of leading institutional healthcare investors.
  • Haynes and Boone, LLP served as legal counsel to BiomX.
  • Wilmer Cutler Pickering Hale and Dorr LLP served as legal counsel to the placement agents.

Emerald Bay Risk Solutions Launches with Strategic Investment from Bain Capital Insurance

Retrieved on: 
Thursday, March 28, 2024
Professional Services, Insurance, Finance, Emerald, McDermott Will & Emery, Longevity, Property, Liberty Mutual, Partnership, General counsel, Business development, Head, Record, QRE, DeBevoise, Martha Plimpton, Amazon Web Services, Bain Capital, AM Best, Excess, Multimedia, Lead, MGA

Emerald Bay Risk Solutions (“Emerald Bay” or the “Company”), a collaborative underwriting carrier, today announced its formal launch with a significant strategic investment from Bain Capital Insurance , the dedicated insurance investing unit of Bain Capital.

Key Points: 
  • Emerald Bay Risk Solutions (“Emerald Bay” or the “Company”), a collaborative underwriting carrier, today announced its formal launch with a significant strategic investment from Bain Capital Insurance , the dedicated insurance investing unit of Bain Capital.
  • Emerald Bay is an innovative program specialist that seeks to create an alignment of interests across the entire risk value chain through integrated solutions and disciplined underwriting enhanced by a proprietary data-driven technology platform.
  • Emerald Bay begins operations with a strong financial foundation, having secured a rating of “A-“ Stable, Financial Size category VIII, from AM Best.
  • Bain Capital Insurance was advised by McDermott Will & Emery and Debevoise & Plimpton LLP.

Cadent Announces Intent to Acquire Performance Advertising Pioneer AdTheorent

Retrieved on: 
Monday, April 1, 2024
McDermott Will & Emery, Procurement, LLP, Advertising, Ecosystem, Machine learning, RBC Capital Markets

NEW YORK, April 1, 2024 /PRNewswire/ -- Cadent, one of the largest independent solutions providers for converged TV advertising, today announced a definitive agreement to acquire all outstanding shares of AdTheorent Holding Company, Inc. (Nasdaq: ADTH), a machine learning pioneer and industry leader delivering measurable value for programmatic advertisers, for a cash consideration of $3.21 per share.

Key Points: 
  • The combination of Cadent and AdTheorent will create one of the largest independent omnichannel audience activation platforms for buyers and sellers of advertising.
  • "Together, Cadent and AdTheorent will enable our customers to drive performance across all strategic audiences, no matter where they consume media or where they are in the sales funnel," said Nick Troiano, CEO of Cadent.
  • "In Cadent, we've found a partner with a shared commitment to delivering measurable results for customers, and a complementary vision for the future of omnichannel advertising.
  • Novacap, the Montreal-based private equity firm which acquired Cadent in August 2023, provided strategic services and funding support to Cadent for the transaction.

McDermott Expands Litigation Practice, Eyes White-Collar and Government Investigation Growth Opportunities

Retrieved on: 
Thursday, March 14, 2024
McDermott Will & Emery, Government, Corruption, New York Law Journal, Sagar, Drug Enforcement Administration, Justice minister, Risk, Operation Car Wash, United States Attorney, Ethics, SDNY, History, Artificial intelligence, FCA, AI, Chambers and Partners, Security (finance), Foreign Corrupt Practices Act, DOJ, False Claims Act, Publication, Tourism, Fraud, FCPA, International law, Private investigator

WASHINGTON, March 14, 2024 /PRNewswire/ -- International law firm McDermott Will & Emery continues to add top talent to its Litigation Practice Group, announcing the following new hires who focus on Foreign Corrupt Practices Act (FCPA) and False Claims Act (FCA) matters and cybercrime:

Key Points: 
  • "These new hires reflect our commitment to looking around corners and providing new strategies clients can use to get ahead of potential enforcement matters."
  • He has consistently been recognized as a leading FCPA lawyer by publications including Chambers USA, Legal 500 and GIR Just Anti-Corruption.
  • Sagar brings almost a decade of experience as a federal prosecutor to advise companies and individuals facing government investigations and enforcement actions.
  • "We are delighted to welcome these partners to our team, extending our capabilities in FCPA and cyber issues, said Steven Scholes , global head of McDermott's Litigation Practice Group.

EQS-News: Heidelberg Pharma Announces Royalty Financing Agreement with HealthCare Royalty for up to USD 115 million

Retrieved on: 
Wednesday, March 13, 2024
Morgan Stanley, Annual report, FDA, Food, Spacecraft, Sale, BLA, ADC, Telix, CAIX, McDermott Will & Emery, Patient, Diagnosis, HPHA, Phase, PET, Positron emission tomography, Pharmaceutical industry

Ladenburg, Germany, 4 March 2024 – Heidelberg Pharma AG (FSE: HPHA), a clinical stage biotech Company developing innovative Antibody Drug Conjugates (ADCs), and HealthCare Royalty (HCRx) today announced that they have signed a royalty financing agreement.

Key Points: 
  • Ladenburg, Germany, 4 March 2024 – Heidelberg Pharma AG (FSE: HPHA), a clinical stage biotech Company developing innovative Antibody Drug Conjugates (ADCs), and HealthCare Royalty (HCRx) today announced that they have signed a royalty financing agreement.
  • Key terms of the agreement between Heidelberg Pharma and HCRx:
    Following the receipt by HCRx of a maximum cumulative amount, royalty payments will revert to Heidelberg Pharma and HCRx will receive a low single digit royalty tail percentage thereafter
    Prof. Dr. Andreas Pahl, Chief Executive Officer at Heidelberg Pharma, commented: “We are delighted to partner with HealthCare Royalty.
  • This agreement will provide us with a non-dilutive financing based on expected royalty payments from the worldwide sales of ZircaixTM.
  • Heidelberg Pharma will hold a conference call on 25 March 2024 with the publication of the Annual Report.

Brevet Capital Names Mei-Li da Silva Vint Chief Commercial Officer

Retrieved on: 
Thursday, February 29, 2024
Consulting, Banking, Professional Services, Finance, Voyager Digital, Growth, Columbia Business School, Market, McDermott Will & Emery, State university system, University, History, Business administration, Law, Virginia Tech, Creativity, Pension, Capital, Woman, PEI, Management

Brevet Capital (“Brevet”), a leading credit investment and specialty finance firm, today announced the appointment of Mei-Li da Silva Vint to Chief Commercial Officer, effective immediately.

Key Points: 
  • Brevet Capital (“Brevet”), a leading credit investment and specialty finance firm, today announced the appointment of Mei-Li da Silva Vint to Chief Commercial Officer, effective immediately.
  • Ms. da Silva Vint is a seasoned professional and longtime executive at Brevet, previously serving as the firm’s Chief Compliance Officer and navigating several of its most complex transactions.
  • With almost two decades of experience executing M&A, private equity, and venture capital transactions, Ms. da Silva Vint possesses a deep expertise within Brevet’s core sectors of focus.
  • Doug Monticciolo, Chief Executive Officer and Co-Founder of Brevet Capital, commented, “Mei-Li is a seasoned, savvy investment professional with a diverse and unique skillset.

Sheppard Mullin Adds Leading Healthcare Partner Megan Rooney in Chicago

Retrieved on: 
Monday, February 26, 2024
Professional Services, Health, Hospitals, Legal, Consulting, General Health, Licensure, Acquisition, Certification, Hospital, Nursing, University, Culture, University School, Sale, Pleasure, UCI, Health care, McDermott Will & Emery, UC, HCA Healthcare, Accreditation, Employment, Privacy, Medical Center, Knowledge, UCLA, Corporation

Sheppard, Mullin, Richter & Hampton LLP is pleased to announce that Healthcare partner Megan Rooney has joined the firm in Chicago.

Key Points: 
  • Sheppard, Mullin, Richter & Hampton LLP is pleased to announce that Healthcare partner Megan Rooney has joined the firm in Chicago.
  • Rooney’s move to Sheppard Mullin comes on the heels of partner Douglas Swill , who also joined the Healthcare industry team in Chicago earlier this month.
  • “Adding Doug and now Megan underscores our strategic focus to continuing to grow our Healthcare team with attorneys who have a deep understanding of the healthcare landscape,” said Luca Salvi, chair of Sheppard Mullin.
  • A former healthcare professional with first-hand clinical experience, Rooney brings unique insight into the business challenges and opportunities facing her clients.